Search Results for: The New Industry Paradigm for
Articles
Enteris BioPharma Highlighted as Game Changer in Special Feature on Innovative Technologies for Improving Drug Solubility & Bioavailability April 7, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary...EXECUTIVE INTERVIEW - Syner-G BioPharma: A Track Record of CMC Excellence April 4, 2022
Prabu Nambiar, PhD, Founder and CEO Syner-G, discusses the company’s evolution, its approach to CMC, and the future of the organization.
SPECIAL FEATURE - Analytical Testing Trends in 2022 January 17, 2022
Contributor Cindy H. Dubin reports on the innovative technologies and techniques that several leading outsourcing providers currently offer for both small and large molecules.
EXOSOMES - The Next Evolution in Therapy Delivery Beyond the Cell Membrane: The Promise of Exosomes January 17, 2022
Linda Marbán, PhD, says perhaps the best way to get past the cell membrane is to deliver contents the same way that cells send information to each other. And that is by the exosome, which in the case of targeted therapy delivery, has been identified as an alternative that shows powerful promise.
BIOMARKERS - Biomarkers: The Guiding Light for R&D in Heterogeneous Diseases January 14, 2022
Thomas Turi, PhD, says while biomarkers have been a long-standing part of R&D and a mainstay of clinical practice for the characterization and diagnosis of disease for decades, they are increasingly playing a crucial role in guiding decisions to improve efficacy and efficiency of clinical trials.
Proscia & Datavant Partner to Connect Pathology Data With Health Data Ecosystem for Life Sciences R&D January 13, 2022
Proscia and Datavant recently announced a partnership that will provide life sciences companies with digitized pathology data to power the development...Cerevel Therapeutics & Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia December 16, 2021
Cerevel Therapeutics and Herophilus recently announced a phased multi-year, joint research collaboration in neuropsychiatry. The collaboration integrates the deep expertise...ESCP Models - Hepatitis C Medications (Part 2), Oral Therapeutics November 3, 2021
Part 2 of this series fills in the story starting with the first oral HCV therapeutic, Vertex’s Incivek (telaprevir), which predated the first of the Gilead therapeutics by 2.5 years…
SPECIAL FEATURE - Injection Devices: Designing Simplicity, Safety & Adherence Into One Delivery System August 26, 2021
Contributor Cindy Dubin, in this annual report, speaks with industry innovators and takes a deep dive into the myriad injectables that are currently in development or recently introduced to the market.
CatSci & Argonaute RNA Partner to Expedite Oligonucleotide Manufacturing for Gene-Silencing Therapeutics July 28, 2021
CatSci Ltd and Argonaute RNA recently announced a chemistry, manufacturing, and control (CMC) development collaboration focused on novel therapeutic oligonucleotides…..
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication July 13, 2021
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication Catalent, the leading...DRUG DEVELOPMENT EXECUTIVE - Enteris BioPharma: How to Build a Preferred CDMO Partner June 1, 2021
Dr. Paul Shields, COO of Enteris BioPharma, discusses the changing face of the CDMO industry and how his company plans to leverage its newly expanded CDMO operations to take advantage of a variety of growth opportunities to build deeper partnerships.
EXECUTIVE INTERVIEW - Micropore: Innovation in Drug Delivery May 3, 2021
Dai Hayward, CEO at Micropore, discusses his company’s expertise and underpinning technology in the development of safe, efficient, and scalable continuous manufacturing of drug delivery solutions.
SPECIAL FEATURE - Improving Bioavailability & Solubility: Each Molecule Is Unique March 1, 2021
Contributor Cindy H. Dubin speaks with several innovative companies to discuss novel approaches to improving bioavailability and solubility that have one commonality: they treat each molecule as an individual.
EXECUTIVE INTERVIEW - BiologIC Technologies: The Future Microsoft for the Biorevolution January 13, 2021
Richard Vellacott, CEO of BiologIC Technologies, discusses his company’s unique technology and its applications in the future of medicine and wider fields of synthetic biology.
BIOSIMILAR DEVELOPMENT - Biosimilars: The Process & Quality System Approach to Clinical Applications January 13, 2021
Kaiser Aziz, PhD, addresses biosimilar developments and future innovations with an emphasis placed on quality system approaches to the development and availability of new biosimilar products.
AiViva Biopharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer October 7, 2020
AiViva Biopharma Inc. recently announced it has begun dosing patients diagnosed with superficial or nodular basal cell carcinoma (BCC) with...EXECUTIVE INTERVIEW - Immunic Therapeutics: Developing Next-Generation Oral Drugs in Chronic Inflammatory, Autoimmune & Infectious Diseases October 1, 2020
Daniel Vitt, PhD, Immunic’s Chief Executive Officer and President, discusses his company’s pipeline of selective, small molecule therapies aimed at treating chronic inflammatory and autoimmune diseases, and its recent progress.
EXECUTIVE INTERVIEW - Enteris BioPharma: Pioneers in Oral Formulation Development September 30, 2020
Dr. Rajiv Khosla, CEO of Enteris BioPharma, discusses how his company’s innovative oral formulation technology is helping the pharmaceutical industry overcome the hurdle of low bioavailability to reshape treatment categories and expand market opportunities with minimal financial and regulatory risks.
OXGENE Introduces TESSA Technology for Robust & Reproducible AAV Manufacture at Scale September 23, 2020
OXGENE recently announced the launch of its scalable, plasmid-free manufacturing system for AAV. OXGENE’s new TESSA technology addresses….
